Yinglin Mark Xu
Chief Executive Officer chez Xynomic Pharmaceuticals, Inc.
Profil
Yinglin Mark Xu is the founder of Bridge Pharmaceuticals, Inc. (founded in 2005), Pacific Biopharma Group (founded in 2005), Xynomic Pharmaceuticals, Inc. (founded in 2016), and Xynomic Pharmaceuticals Holdings, Inc. (founded in 2016).
At Xynomic Pharmaceuticals, Inc., he holds the titles of Chairman, President & Chief Executive Officer.
He previously worked at The Trout Group LLC as General Manager-Greater China from 2009 to 2016.
Mr. Xu holds an MBA from Stanford University, an undergraduate degree from Hanover College, and a graduate degree from Purdue University.
Postes actifs de Yinglin Mark Xu
| Sociétés | Poste | Début |
|---|---|---|
Xynomic Pharmaceuticals, Inc.
 Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Chief Executive Officer | 01/01/2016 |
Anciens postes connus de Yinglin Mark Xu
| Sociétés | Poste | Fin |
|---|---|---|
The Trout Group LLC
 The Trout Group LLC Financial ConglomeratesFinance The Trout Group LLC operates as an investor relations and strategic advisory firm servicing the life science industry. It offers investor relations strategy, targeting and outreach, market intelligence, investor relation event planning and execution, investor relations materials, and corporate communications services. The company was founded by Jonathan B. Fassberg in 2004 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2016 |
| Pacific Biopharma Group | Founder | 01/01/2009 |
Bridge Pharmaceuticals, Inc.
 Bridge Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs. | Founder | 01/01/2009 |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Chief Executive Officer | - |
Formation de Yinglin Mark Xu
| Stanford University | Masters Business Admin |
| Hanover College | Undergraduate Degree |
| Purdue University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Bridge Pharmaceuticals, Inc.
Bridge Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs. | Commercial Services |
The Trout Group LLC
The Trout Group LLC Financial ConglomeratesFinance The Trout Group LLC operates as an investor relations and strategic advisory firm servicing the life science industry. It offers investor relations strategy, targeting and outreach, market intelligence, investor relation event planning and execution, investor relations materials, and corporate communications services. The company was founded by Jonathan B. Fassberg in 2004 and is headquartered in New York, NY. | Finance |
| Pacific Biopharma Group | |
Xynomic Pharmaceuticals, Inc.
Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Health Technology |
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
